Scientific ground for what your product promises
BiCT is the R&D partner of companies developing cosmetics and medical devices. We verify safety and efficacy on reconstructed human models in vitro, and we supply biotech ingredients of our own. Not isolated tests: the evidence it takes to bring a product to market and to defend it.
Let’s talk about your project
Three paths, three ways of working with us
The starting point is not the test: it is the product in your hands and the decision you have to make.
If you develop finished cosmetics
Brands, contract manufacturers and formulation houses launching a new reference or strengthening the ones already in the catalogue. You need a product that holds up on the shelf and a dossier that holds up with the regulator.
What you need: safety assessment for the PIF · efficacy evidence on the finished product · benchmarking against reference products · scientific narrative for the sales force · support in choosing the actives.
If you develop medical devices
Products acting on mucosae — respiratory, oral, oesophageal, rectal — that fall under Regulation (EU) 2017/745, not 1223/2009. A different regulatory frame, different experimental models, a different vocabulary.
What you need: mucoadhesion and barrier effect · mucolytic and fluidifying action · cytoprotection on 3D reconstructed epithelium · cytotoxicity to ISO 10993-5 · evidence for the technical file.
If you produce ingredients
Manufacturers of actives and extracts who need to show what their raw material does, and to show it to whoever will formulate with it. A path we follow on request, covering testing and characterisation.
What you need: characterisation of biological activity · mechanism of action on 3D skin models · comparison with category references · data for the technical dossier addressed to your downstream customers.
A claim is not sustained by a promise
The cosmetics market is more crowded and more closely controlled than it used to be. Regulation 1223/2009 requires every label statement to be supported by documented evidence; buyers ask for data; consumers ask to understand.
Without credible models and data of its own, a product does not get selected, does not get defended and does not get recommended.
What we solve
From the problems clients bring us to the tests that close them: every project starts from a decision to be made, not from a catalogue code.
Reconstructed human models, no shortcuts
No animal testing: it has been banned for cosmetics in Europe since 2013, and the in vitro models we use today tell us more than it ever did. Over 200 studies carried out with these systems since 2018.
Reconstructed 3D skin and epithelia
Our reference model, and the one most used across the projects we run: reconstructed human epidermis and mucosae, where irritation, cytoprotection, barrier effect and the response to an active are observed on a stratified, viable tissue.
Cell cultures and microbiology
Keratinocytes and fibroblasts for mechanisms of action, and a broad strain collection for antimicrobial, anti-biofilm, antiviral and prebiotic activity — through to qPCR and metagenomics on swabs from your in vivo studies.
Chemistry and enzymology
Analytical method development, antioxidant capacity by the TEAC method, enzyme inhibition and AGE fluorescence measurement for anti-glycation: the assays that quantify what the cell models show.
Three biotech ingredients, ours
Developed and produced in house, with the evidence dossier already built. If you formulate a finished product you can start here, instead of hunting for an active that does what you need.
Six concrete reasons, for R&D, Marketing and Regulatory
Studies do not end up in a report: they become arguments used inside the company and out on the market.
Where do we start?
I am developing a finished cosmetic
I am developing a medical device
I am not sure where to begin
Insights
Technical articles from the division: what has to be demonstrated, how it is measured and what it costs, with data from our projects.
The bottleneck is not the method: ECHA’s sixth reportEvery few years ECHA publishes a report on how far alternatives to animal testing are actually used in REACH dossiers. This year the numbers say one […]Read →
Upcycling: when a by-product becomes an ingredientA by-product becomes a cosmetic ingredient only if it is available, consistent and characterised. The conditions that decide whether the project stands up.Read →
Microbiota-friendly: from trend to claimMicrobiota-friendly is on more and more labels. What you need to have measured before it becomes a defensible claim rather than a promise.Read →Projects we can talk about
Some of the projects we have worked on with cosmetic companies and brands.
CIRCLETEXCIRCLETEX combines expertise in mechatronics, green chemistry, and biotechnology to create an innovative value chain based on the valorization of textile waste.Read →
Scent of LombardyThe project is aimed at the creation of a technological platform that can be accessed by perfume companies interested in eco-sustainable components.Read →
BiocosmBIOCOSM project carried out experimental activities in the sustainable preparation of high value cosmetic ingredients.Read →Frequently asked questions
No: we work on reconstructed human tissues and cells, following OECD guidelines.
Safety, anti-ageing, barrier and soothing, skin microbiome, tone and UV protection, on the finished product or on the ingredient.
Yes, on substance-based devices under Regulation (EU) 2017/745, district by district.
Our experience at the service of important projects.
The next one could be yours!
Being innovative means being passionate about evolving what already exists in order to improve it, bringing a valuable contribution to health, environment and sustainable development: let’s get in touch and find the best way to make the difference.
Contact us